Enbrel®

Generic Name: Etanercept
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20021618Early Rheumatoid Arthritis3b

Open-label Extension Treatment with TNFR:Fc for Participating Patients in TNFR:Fc Clinical Trials

20021623TNFR:Fc3b

Open-label Extension Treatment with TNFR:Fc for Participating Patients in TNFR:Fc Clinical Trial 016.0012

20021626Juvenile Rheumatoid Arthritis4

A Phase IV Registry of Etanercept in Children with Juvenile Rheumatoid Arthritis

20021631Systemic Onset3

A Phase 3 Safety and Efficacy Study of Etanercept in Children With Systemic Onset Juvenile Rheumatoid Arthritis

20040131Psoriatic Arthritis4

REPArE (Rating Evaluations in Psoriatic Arthritis with Enbrel®)

20040136Approved etanercept indications1An Open-label, Randomized, 2-period Crossover Bioequivalence Study Comparing a 50-mg Dose of Liquid Etanercept Administered to Healthy Subjects by Subcutaneous Injection in the Thigh Using an Auto-injector Device and Manual Injection
20040171Psoriasis4A Multicenter, Open-label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL; in Combination With Narrowband UV-B Phototherapy for the Treatment of Psoriasis(UNITE - Utilization of Narrowband UVB Light Therapy and Etanercept for the Treatment of Psoriasis)
20040201Rheumatoid Arthritis (RA)4An Open-Label, Randomized, Crossover Study to Assess Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Prefilled Syringes
20040210Psoriasis4

Observational Post-Marketing Safety Surveillance Registry of Enbrel® (etanercept) for the Treatment of Psoriasis (OBSERVE-5™)

20040275Rheumatoid Arthritis (RA)4A Multi-center, Randomized, Double-Blind, Active - Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly
20050145Rheumatoid Arthritis3bOpen-label Study to Assess the Antibody Response to Etanercept Liquid Subjects with Rheumatoid Arthritis
20050180Psoriasis4

CAN-EASE (Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel in Psoriasis)

20050207Rheumatoid Arthritis4An Open-label Study to Assess the Rate of Failure of an Enbrel (etanercept)SureClick? Auto-injector in Subjects With Rheumatoid Arthritis
20060104Rheumatoid Arthritis (RA)3bOpen-label Study to Assess the Safety and Immunogenicity of Etanercept Serum-free Process When Administered to Subjects Diagnosed With Rheumatoid Arthritis
20060118Rheumatoid Arthritis1

DCE-MRI of the Wrist to Measure Short-Term Responses in Rheumatoid Arthritis Subjects Treated With Etanercept

20070301Rhematoid Arthritis4

CAnadian Methotrexate and Etanercept Outcome Study: An Open-label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)

20070559Moderate to Severe Plaque Psoriasis3b

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

20070561Moderately Active Rheumatoid Arthritis4

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therap

20080014Moderate to Severe Plaque Psoriasis4

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis

20080470Moderate to Severe Plaque Psoriasis3b

A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

20090176Rheumatoid Arthritis and Plaque Psoriasis4

An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated with Etanercept

20090647Moderate to Severe Plaque Psoriasis3b

A Randomized, Blinded Assessor Study to Evaluate the Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent Versus Etanercept 50 mg Twice Weekly in Subjects with Moderate to Severe Plaque Psoriasis (REFINE)

20101145Plaque Psoriasis4Open-label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate-to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab.
20110107Rheumatoid Arthritis or Psoriatic Arthritis 3b

A Single-arm, Multicenter Study to Evaluate the Ability of Subjects with Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept

20120125 Moderate to severe Rheumatoid Arthritis4A Single-arm Trial to Evaluate the Efficacy of Etanercept in Moderate-to-Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment with Adalimumab When Used as Their First Biologic Agent (ROCkIES)